行情

ICCC

ICCC

ImmuCell
NASDAQ

实时行情|Nasdaq Last Sale

5.20
-0.10
-1.89%
已收盘, 16:00 02/20 EST
开盘
5.20
昨收
5.30
最高
5.36
最低
5.15
成交量
2.42万
成交额
--
52周最高
8.13
52周最低
4.700
市值
3,748.99万
市盈率(TTM)
-16.3522
分时
5日
1月
3月
1年
5年

ICCC 新闻

  • Edited Transcript of ICCC earnings conference call or presentation 19-Feb-20 2:00pm GMT
  • Thomson Reuters StreetEvents.1天前
  • ImmuCell Corporation (ICCC) CEO Michael Brigham on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.1天前
  • ImmuCell Announces Correction to its Reported Unaudited Loss Per Share from ($0.06) to ($0.04) for the Quarter Ended December 31, 2019
  • GlobeNewswire.1天前
  • The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA
  • Benzinga.1天前

更多

所属板块

生物技术和医学研究
+0.09%
制药与医学研究
-0.40%

热门股票

名称
价格
涨跌幅

ICCC 简况

ImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis. The Company's lead product, First Defense, is manufactured from cows' colostrum utilizing its vaccine and milk protein purification technologies. Its Wipe Out Dairy Wipes are made from a non-woven fabric that allows for a vigorous cleaning. It also developed California Mastitis Test (CMT), which is used for bulk tank, as well as individual cow sample monitoring and is used to determine which quarter of the udder is mastitic. Its product development initiative is Mast Out, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows.
展开

Webull提供ImmuCell Corporation的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。